{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:30:12Z","timestamp":1790040612400,"version":"4.0.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.omtn.2023.04.026","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T02:46:18Z","timestamp":1683168378000},"page":"729-742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration"],"prefix":"10.1016","volume":"32","author":[{"given":"Rui","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3814-2026","authenticated-orcid":false,"given":"Xiuyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keda","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-7870","authenticated-orcid":false,"given":"Jia","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2023.04.026_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010117","article-title":"Chronic myeloid leukemia: a model disease of the past, present and future","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2023.04.026_bib2","doi-asserted-by":"crossref","first-page":"106523","DOI":"10.1016\/j.leukres.2021.106523","article-title":"Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells","volume":"102","author":"Ozkan","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.omtn.2023.04.026_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194820","article-title":"Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.omtn.2023.04.026_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/jnci\/djt029","article-title":"Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2","volume":"105","author":"Cogle","year":"2013","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.omtn.2023.04.026_bib5","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J.\u00a0Allergy Clin. Immunol."},{"key":"10.1016\/j.omtn.2023.04.026_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1146\/annurev.pathol.4.110807.092222","article-title":"MicroRNAs in cancer","volume":"4","author":"Lee","year":"2009","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.omtn.2023.04.026_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/1477-7819-12-137","article-title":"Prognostic significance of TMEM16A, PPFIA1, and FADD expression in invasive ductal carcinoma of the breast","volume":"12","author":"Choi","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.omtn.2023.04.026_bib8","article-title":"Prognostic role of microRNA-181a\/b in hematological malignancies: a meta-analysis","volume":"8","author":"Lin","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.04.026_bib9","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s11033-019-04712-y","article-title":"Combined expression and prognostic significance of PPFIA1 and ALG3 in head and neck squamous cell carcinoma","volume":"46","author":"Zhou","year":"2019","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.omtn.2023.04.026_bib10","first-page":"3862","article-title":"Liprin-\u03b11, ERC1 and LL5 define polarized and dynamic structures that are implicated in cell migration","volume":"127","author":"Astro","year":"2014","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2023.04.026_bib11","series-title":"circ_0080145 Enhances Imatinib Resistance of Chronic Myeloid Leukemia by Regulating miR-326\/PPFIA1 Axis","author":"Che","year":"2020"},{"key":"10.1016\/j.omtn.2023.04.026_bib12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s13238-015-0143-7","article-title":"Leukemia stem cells: the root of chronic myeloid leukemia","volume":"6","author":"Zhou","year":"2015","journal-title":"Protein Cell"},{"issue":"Suppl 4","key":"10.1016\/j.omtn.2023.04.026_bib13","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.3816\/CLM.2009.s.037","article-title":"The chronic myeloid leukemia stem cell","volume":"9","author":"Nicholson","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"key":"10.1016\/j.omtn.2023.04.026_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1158\/1078-0432.CCR-16-0226","article-title":"Anthelmintic Niclosamide disrupts the interplay of p65 and FOXM1\/\u03b2-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia","volume":"23","author":"Jin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omtn.2023.04.026_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1365-2141.2008.07197.x","article-title":"Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease","volume":"142","author":"Valent","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.omtn.2023.04.026_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/978-3-319-97746-1_6","article-title":"Preservation of quiescent chronic myelogenous leukemia stem cells by the bone marrow microenvironment","volume":"1100","author":"Shah","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omtn.2023.04.026_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s12185-010-0615-8","article-title":"Molecular pathways to CML stem cells","volume":"91","author":"Rice","year":"2010","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.omtn.2023.04.026_bib18","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.4161\/15476286.2014.972853","article-title":"RNAa in action: from the exception to the norm","volume":"11","author":"Guo","year":"2014","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtn.2023.04.026_bib19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2174\/1389201019666180611093428","article-title":"Development of MTL-CEBPA: small activating RNA drug for hepatocellular carcinoma","volume":"19","author":"Setten","year":"2018","journal-title":"Curr. Pharmaceut. Biotechnol."},{"key":"10.1016\/j.omtn.2023.04.026_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.6026\/97320630002235","article-title":"RNAi and RNAa--the yin and yang of RNAome","volume":"2","author":"Pushparaj","year":"2008","journal-title":"Bioinformation"},{"key":"10.1016\/j.omtn.2023.04.026_bib21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/wrna.90","article-title":"Small RNA and transcriptional upregulation","volume":"2","author":"Portnoy","year":"2011","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.omtn.2023.04.026_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4155\/tde-2018-0061","article-title":"Developing small activating RNA as a therapeutic: current challenges and promises","volume":"10","author":"Kwok","year":"2019","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.omtn.2023.04.026_bib23","doi-asserted-by":"crossref","first-page":"22893","DOI":"10.18632\/oncotarget.8290","article-title":"Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.omtn.2023.04.026_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153117","article-title":"C\/EBP\u03b1 short-activating RNA suppresses metastasis of hepatocellular carcinoma through inhibiting EGFR\/\u03b2-Catenin signaling mediated EMT","volume":"11","author":"Huan","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.omtn.2023.04.026_bib25","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1566523218666180619155018","article-title":"Current advances in small activating RNAs for gene therapy: principles, applications and challenges","volume":"18","author":"Zhou","year":"2018","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtn.2023.04.026_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/1566523219666190708111404","article-title":"The therapeutic potential of small activating RNAs for colorectal carcinoma","volume":"19","author":"Zheng","year":"2019","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtn.2023.04.026_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/EXP.20210008","article-title":"Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment","volume":"1","author":"Guo","year":"2021","journal-title":"Explorations"},{"key":"10.1016\/j.omtn.2023.04.026_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm1418","article-title":"Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia","volume":"8","author":"Hu","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2023.04.026_bib29","article-title":"Small activating RNA modulation of the G protein-coupled receptor for cancer treatment","volume":"9","author":"Xiong","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.omtn.2023.04.026_bib30","article-title":"Advances of nanoparticles as drug delivery systems for disease diagnosis and treatment","volume":"34","author":"Liu","year":"2023","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.omtn.2023.04.026_bib31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","article-title":"Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: a review","volume":"38","author":"Singh","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.omtn.2023.04.026_bib32","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.3892\/ol.2015.3663","article-title":"MicroRNA-181a enhances the chemotherapeutic sensitivity of chronic myeloid leukemia to imatinib","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.omtn.2023.04.026_bib33","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.31557\/APJCP.2021.22.10.3237","article-title":"CD34+\/CD38- stem cell burden could predict chronic myeloid leukemia patients' outcome","volume":"22","author":"Fathy El-Metwaly","year":"2021","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"key":"10.1016\/j.omtn.2023.04.026_bib34","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1166\/jbn.2015.2147","article-title":"Modulating the growth and imatinib sensitivity of chronic myeloid leukemia stem\/progenitor cells with pullulan\/MicroRNA nanoparticles in\u00a0vitro","volume":"11","author":"Ma","year":"2015","journal-title":"J.\u00a0Biomed. Nanotechnol."},{"issue":"Suppl 1","key":"10.1016\/j.omtn.2023.04.026_bib35","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s00280-010-1513-8","article-title":"Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor","volume":"67","author":"Wang","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.omtn.2023.04.026_bib36","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/DDDT.S89114","article-title":"Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells","volume":"10","author":"Abbaspour Babaei","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtn.2023.04.026_bib37","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1158\/0008-5472.CAN-13-1318","article-title":"KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors","volume":"73","author":"Corbin","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2023.04.026_bib38","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2018-06-858159","article-title":"Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice","volume":"133","author":"Pang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.04.026_bib39","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/blood.V92.7.2461","article-title":"Stem cell factor as a single agent induces selective proliferation of the Philadelphia chromosome positive fraction of chronic myeloid leukemia CD34(+) cells","volume":"92","author":"Moore","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2023.04.026_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-5-46","article-title":"The stem cell factor\/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells","volume":"5","author":"Yasuda","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.omtn.2023.04.026_bib41","article-title":"Loss of FGFR3 delays acute myeloid leukemogenesis by programming weakly pathogenic cd117-positive leukemia stem-like cells","volume":"11","author":"Guo","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2023.04.026_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2021.01.003","article-title":"Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells","volume":"95","author":"Russkamp","year":"2021","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.omtn.2023.04.026_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.015","article-title":"Discovery of the oncogenic Parp1, a target of bcr-abl and a potential therapeutic, in mir-181a\/PPFIA1 signaling pathway","volume":"16","author":"Gu","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2023.04.026_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000357373","article-title":"CD117 (c-kit) expression on CD34+ cells participates in the cytogenetic response to imatinib in patients with chronic myeloid leukemia in the first chronic phase","volume":"132","author":"Dybko","year":"2014","journal-title":"Acta Haematol."},{"key":"10.1016\/j.omtn.2023.04.026_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"Suppl","key":"10.1016\/j.omtn.2023.04.026_bib46","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35 Suppl","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.omtn.2023.04.026_bib47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.omtn.2023.04.026_bib48","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.omtn.2023.04.026_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-10-4310-9_1","article-title":"Small RNA-guided transcriptional gene activation (RNAa) in mammalian cells","volume":"983","author":"Li","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.omtn.2023.04.026_bib50","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1101\/gad.1158803","article-title":"Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs","volume":"17","author":"Yi","year":"2003","journal-title":"Genes Dev."},{"key":"10.1016\/j.omtn.2023.04.026_bib51","doi-asserted-by":"crossref","first-page":"518","DOI":"10.2174\/138920110791591463","article-title":"Defining features and exploring chemical modifications to manipulate RNAa activity","volume":"11","author":"Place","year":"2010","journal-title":"Curr. Pharmaceut. Biotechnol."}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123001129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253123001129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T16:14:28Z","timestamp":1730736868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253123001129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":51,"alternative-id":["S2162253123001129"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2023.04.026","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742681532.793599109","asserted-by":"object"}]},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2023.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}]}}